TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26017787

Group type: EXPERIMENTAL
Intervention: Birth preparation program including supervised physical exercise, relaxation exercises, and educational activities
Number of subjects: 0
Study: 24096865

Group type: EXPERIMENTAL
Intervention: Listening training (7 sessions over 1 month)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hearing aids without training (Control group)
Number of subjects: 36
Study: 17049347

Group type: EXPERIMENTAL
Intervention: Two femoral neck screws with intramedullary nails
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single femoral neck screw with intramedullary nails
Number of subjects: 0
Study: 15023570

Group type: EXPERIMENTAL
Intervention: sonepiprazole
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 467

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 467
Study: 10919295

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9014063

Group type: EXPERIMENTAL
Intervention: 6% HES 120/0.7
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6% dextran 70
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 48
Study: 1488359

Group type: EXPERIMENTAL
Intervention: 400 micrograms misoprostol (Cytotec‐Searle)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Aminophylline i.v. infusion at a rate of 500 mg/hour
Number of subjects: 8
Study: 3548986

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 36

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 36
Study: 31235074

Group type: EXPERIMENTAL
Intervention: Tisseel (fibrin sealant) in combination with surgical anastomosis
Number of subjects: 57

Group type: COMPARATOR
Intervention: Surgical anastomosis alone (Control)
Number of subjects: 57
Study: 31002834

Group type: EXPERIMENTAL
Intervention: Oral sedation with triazolam and intravenous placebo
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous sedation with midazolam and oral placebo
Number of subjects: 85
Study: 28153000

Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Transcare Intervention (in addition to usual care)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Usual Care Group
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Cardiac-Diabetes Transcare Intervention
Number of subjects: 432
Study: 25801552

Group type: EXPERIMENTAL
Intervention: sublingual artemether (ArTiMist) 3.0 mg/kg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: sublingual artemether
Number of subjects: 91
Study: 23563070

Group type: EXPERIMENTAL
Intervention: Integrated self-management program
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 21864137

Group type: EXPERIMENTAL
Intervention: Phytoestrogen supplements with exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with exercise
Number of subjects: 40
Study: 19675959

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) program
Number of subjects: 56

Group type: COMPARATOR
Intervention: Information-only control program
Number of subjects: 56
Study: 16919743

Group type: EXPERIMENTAL
Intervention: Positive therapeutic alliance
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Therapists' perceptions of alliance
Number of subjects: 753

Group type: COMPARATOR
Intervention: Treatment compliance
Number of subjects: 753
Study: 15311287

Group type: EXPERIMENTAL
Intervention: Intervention hospitals (230 women)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Control hospitals (426 women)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Physicians from intervention hospitals (72 physicians)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Physicians from control hospitals (70 physicians)
Number of subjects: 656
Study: 11516922

Group type: EXPERIMENTAL
Intervention: Lofexidine, oxazepam, baclofen, ketoprofene, naloxone, naltrexone for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clonidine, oxazepam, baclofen, ketoprofene, naloxone, naltrexone for 3 days
Number of subjects: 40
Study: 9062473

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) 9.5 micrograms/kg daily for 9 months
Number of subjects: 30
Study: 7691256

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (400 micrograms) for 7 days subcutaneously after chemotherapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 3741107

Group type: EXPERIMENTAL
Intervention: Immediate fixation of all fractures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative orthopedic management (traction or plaster casts)
Number of subjects: 0
Study: 29134488

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-assisted program (CPAP)
Number of subjects: 85
Study: 26315844

Group type: EXPERIMENTAL
Intervention: Inpatient treatment (2 or 6 months)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Ambulatory treatment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study: 24487732

Group type: EXPERIMENTAL
Intervention: Desflurane at 0.3 MAC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.3 MAC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Desflurane at 0.5 MAC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Desflurane at 0.7 MAC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.7 MAC
Number of subjects: 14
Study: 23011560

Group type: EXPERIMENTAL
Intervention: 300 mg oral gabapentin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 600 mg oral gabapentin
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 20556208

Group type: EXPERIMENTAL
Intervention: Daily use of long-acting beta2-agonist (LABA) for 12 weeks with conventional reversibility test (2 puffs terbutaline)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Daily use of long-acting beta2-agonist (LABA) for 12 weeks with reversibility test using refracted doses (1 puff every 5 min, total 4 puffs)
Number of subjects: 28
Study: 18652709

Group type: EXPERIMENTAL
Intervention: Penile block using 0.25 mL kg(‐1) 0.5% bupivacaine (Group P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Caudal block using 0.5 mL kg(‐1) 0.25% bupivacaine with 0.5 mg kg(‐1) ketamine (Group C)
Number of subjects: 40
Study: 15956998

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Multivitamins (B, C, and E)
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Multivitamins including A
Number of subjects: 716

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 716
Study: 12866218

Group type: EXPERIMENTAL
Intervention: Johnson and Toshach technique
Number of subjects: 504
Study: 10553833

Group type: EXPERIMENTAL
Intervention: 50% ropivacaine (1%) and 50% lidocaine (2%) with 25 U hyaluronidase per mL
Number of subjects: 100

Group type: COMPARATOR
Intervention: 50% bupivacaine (0.5%) and 50% lidocaine (2%) with 25 U hyaluronidase per mL
Number of subjects: 100
Study: 8656441

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin [100 mg/m2] on day 1, followed by fluorouracil [1000 mg/m2 per day] on days 1-5)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Immediate surgery with postoperative radiotherapy (50-70 Gy)
Number of subjects: 194
Study: 1804657

Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Niacin (50 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6837864

Group type: EXPERIMENTAL
Intervention: Shaving
Number of subjects: 253

Group type: COMPARATOR
Intervention: Depilatory cream
Number of subjects: 253
Study: 31271587

Group type: EXPERIMENTAL
Intervention: Aerobic training on dry land
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined training on dry land
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined training in water
Number of subjects: 55

Group type: COMPARATOR
Intervention: Without training
Number of subjects: 55
Study: 28566591

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day) plus Aspirin (100 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 24
Study: 26549616

Group type: EXPERIMENTAL
Intervention: Experimenter-enforced associative encoding strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mandated rote rehearsal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encouraged time and effort toward encoding with strategy choice
Number of subjects: 0
Study: 25118156

Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Upper Limb (FST-UL)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Functional Strength Training for Lower Limb (FST-LL)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Functional Strength Training (FST)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 22975928

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (GPi)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (STN)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT)
Number of subjects: 161
Study: 19383585

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 410

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 410
Study: 17885895

Group type: EXPERIMENTAL
Intervention: Social Communication Questionnaire (SCQ)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Developmental Behaviour Checklist‐Autism Screening Algorithm (DBC‐ASA)
Number of subjects: 49
Study: 15129422

Group type: EXPERIMENTAL
Intervention: Nefazodone (maximum dose 600 mg/day; average dose 463 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sertraline (maximum dose 200 mg/day; average dose 153 mg/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (Nefazodone and Sertraline)
Number of subjects: 37
Study: 12489352

Group type: EXPERIMENTAL
Intervention: Weak isometric plantar-flexion at 20% of maximum voluntary contraction
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Weak isometric dorsiflexion at 20% of maximum voluntary contraction
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Test-stimulus intensity
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Smaller test stimuli
Number of subjects: 15
Study: 9515532

Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor (UTI) administered for 5 consecutive days at a dose of 300,000 units per day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urinary trypsin inhibitor (UTI)
Number of subjects: 16
Study: 8070304

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 15 mg twice daily for 4 weeks
Number of subjects: 10
Study: 3123117

Group type: EXPERIMENTAL
Intervention: Oral etidronate (700‐1400 mg daily for 1 month)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intravenous etidronate (300 mg daily for 5 days)
Number of subjects: 17
Study: 31237000

Group type: EXPERIMENTAL
Intervention: Prospectively registered trials
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Retrospectively registered trials
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Not registered trials
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Indeterminate registration trials
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Trials with registration number reported
Number of subjects: 151
Study: 28355112

Group type: EXPERIMENTAL
Intervention: Chlorambucil plus Rituximab
Number of subjects: 454

Group type: COMPARATOR
Intervention: Chlorambucil alone
Number of subjects: 454

Group type: COMPARATOR
Intervention: Rituximab alone
Number of subjects: 454

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 454
Study: 25658881

Group type: EXPERIMENTAL
Intervention: Prehospital plasma transfusion during air medical transport
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prehospital plasma transfusion
Number of subjects: 6
Study: 23474847

Group type: EXPERIMENTAL
Intervention: Topical 4% strontium chloride (TriCalm®)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control vehicle
Number of subjects: 32

Group type: COMPARATOR
Intervention: 1% hydrocortisone
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2% diphenhydramine
Number of subjects: 32
Study: 21484081

Group type: EXPERIMENTAL
Intervention: Single Step Dilatational Tracheostomy (SSDT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Guide Wire Dilating Forceps (GWDF)
Number of subjects: 120
Study: 17851665

Group type: EXPERIMENTAL
Intervention: High-resolution first-pass myocardial perfusion imaging (HRPI) at 3 T
Number of subjects: 60
Study: 16506054

Group type: EXPERIMENTAL
Intervention: Human insulin inhalation powder (HIIP) plus insulin glargine
Number of subjects: 228

Group type: COMPARATOR
Intervention: Subcutaneously injected insulin (SC insulin) plus insulin glargine
Number of subjects: 228
Study: 15179836

Group type: EXPERIMENTAL
Intervention: Carmofur
Number of subjects: 150

Group type: COMPARATOR
Intervention: Carboquone
Number of subjects: 150
Study: 11078261

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg/twice daily) for 72 hours
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aspirin (250 mg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (unstable angina patients without ticlopidine)
Number of subjects: 160
Study: 8632075

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1471412

Group type: EXPERIMENTAL
Intervention: Immunopotentiating reconstituted influenza virosomes (IRIVs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alum-adsorbed vaccine (Control)
Number of subjects: 100
Study: 6319337

Group type: EXPERIMENTAL
Intervention: Purified form of wheat fibre (10.5 g/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study: 2877413

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion with isotonic saline
Number of subjects: 18
Study: 29953106

Group type: EXPERIMENTAL
Intervention: Collagen biomaterial (Collost)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 75
Study: 28466619

Group type: EXPERIMENTAL
Intervention: Medical clown present during venipuncture (n=29)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No medical clown present during venipuncture (n=24)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Medical clown present
Number of subjects: 53

Group type: COMPARATOR
Intervention: No medical clown present
Number of subjects: 53
Study: 26056101

Group type: EXPERIMENTAL
Intervention: RPT 450 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: RPT 600 mg
Number of subjects: 153

Group type: COMPARATOR
Intervention: RMP 600 mg
Number of subjects: 153
Study: 23435121

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment with additional computerized probe procedure for attentional bias modification
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo variant of the computerized probe procedure
Number of subjects: 134
Study: 20795418

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg every 8 hours)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control (no metoclopramide)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study: 18408370

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation, 1 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Phenytoin therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study: 16677697

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12873294

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 23
Study: 10643696

Group type: EXPERIMENTAL
Intervention: Active treatment (various second-line drugs including methotrexate, cyclosporine plus MTX, and others)
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435
Study: 8797406

Group type: EXPERIMENTAL
Intervention: Theophylline (Uniphyl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study: 1521940

Group type: EXPERIMENTAL
Intervention: CK: carbonated 10% glucose-fructose solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NCK: non-carbonated 10% glucose-fructose solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: CNK: carbonated non-caloric solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: NCNK: non-carbonated non-caloric solution
Number of subjects: 8
Study: 6476044

Group type: EXPERIMENTAL
Intervention: Primary capsulotomy
Number of subjects: 288

Group type: COMPARATOR
Intervention: Intact capsule
Number of subjects: 288
Study: 30878823

Group type: EXPERIMENTAL
Intervention: Social network (stronger social network)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Current driving status
Number of subjects: 147
Study: 29045255

Group type: EXPERIMENTAL
Intervention: Relaxing music therapy intervention (20 minutes, 3 times a day for 3 consecutive days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Silence (control group)
Number of subjects: 17
Study: 26456348

Group type: EXPERIMENTAL
Intervention: Simulation-based neonatal resuscitation curriculum
Number of subjects: 33

Group type: COMPARATOR
Intervention: Lecture-based neonatal resuscitation curriculum
Number of subjects: 33
Study: 23884719

Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 215

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 215
Study: 22052702

Group type: EXPERIMENTAL
Intervention: DRAAAS (dose regimen of artesunate and amodiaquine based on arm span- or age range)
Number of subjects: 68

Group type: COMPARATOR
Intervention: SDRAA (standard dose regimen of artesunate and amodiaquine calculated according to body weight)
Number of subjects: 68
Study: 20210909

Group type: EXPERIMENTAL
Intervention: Recreational football training (F)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endurance running (R)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 50
Study: 18381226

Group type: EXPERIMENTAL
Intervention: Natural condition with asymmetric visual distractor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror-reversed condition with asymmetric visual distractor
Number of subjects: 0
Study: 15861266

Group type: EXPERIMENTAL
Intervention: Formal IBD education
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 69
Study: 12181715

Group type: EXPERIMENTAL
Intervention: Oral sip feed containing 500 kcal of energy and 16.66 g of protein in addition to daily oral intake
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 9842606

Group type: EXPERIMENTAL
Intervention: Exposure to printed advertisements with attractive overweight models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to printed advertisements with models who were not overweight
Number of subjects: 0
Study: 8076537

Group type: EXPERIMENTAL
Intervention: Azelastine nasal solution 2 sprays per nostril bid
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Azelastine nasal solution 2 sprays per nostril qd
Number of subjects: 247

Group type: COMPARATOR
Intervention: Chlorpheniramine 12 mg bid
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 2635353

Group type: EXPERIMENTAL
Intervention: Mexiletine 250 mg i.v. + 200 mg orally followed by 200 mg every 8 h for 48 h
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mexiletine treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine treatment only (Control)
Number of subjects: 32
Study: 337854

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg or 10 mg alone or with promethazine 6.25 mg, 12.5 mg, or 25 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Promethazine 25 mg alone
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Promethazine doses larger than 12.5 mg
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: All drugs (morphine and promethazine)
Number of subjects: 270
Study: 30955985

Group type: COMPARATOR
Intervention: Ibuprofen plus placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus baclofen 10 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus metaxalone 400 mg
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus tizanidine 2 mg
Number of subjects: 320
Study: 29770393

Group type: EXPERIMENTAL
Intervention: Pomegranate consumption
Number of subjects: 0
Study: 27127346

Group type: EXPERIMENTAL
Intervention: Erythromycin (12 months treatment, group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Erythromycin (6 months treatment followed by 6 months follow-up, group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Erythromycin (both groups A and B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study: 23829810

Group type: EXPERIMENTAL
Intervention: Standard essential oil blend
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Customized aromatherapy treatment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 192
Study: 22409423

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix graft (ADMG) with enamel matrix derivative (EMD)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Acellular dermal matrix graft (ADMG) alone
Number of subjects: 19
Study: 19306597

Group type: EXPERIMENTAL
Intervention: CPP-ACP containing products
Number of subjects: 0
Study: 17503687

Group type: EXPERIMENTAL
Intervention: Negative mood induction procedure in older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative mood induction procedure in younger adults
Number of subjects: 0